Pharmakologische Therapie des lokal fortgeschrittenen und metastasierten Harnblasenkarzinoms

  • S. Machtens
  • P. Schöffski
  • M. Kuczyk

Zusammenfassung

Das Harnblasenkarzinom ist ein häufig diagnostizierter maligner Tumor mit einer weltweit ansteigenden Neuerkrankungsrate. Während die globale Inzidenz mit 261.000 angenommen wird, versterben jährlich etwa 115.000 Menschen an dieser Erkrankung [43].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    American Society of Clinical Oncology (1994) Recommendations for the use of hematopoitic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471–2508Google Scholar
  2. [2]
    American Society of Clinical Oncology (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14:1957–1960Google Scholar
  3. [3]
    Anonymous: Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomized controlled trial. Lancet 354:533–540, 1999CrossRefGoogle Scholar
  4. [4]
    Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG: Long-term survival in metastatic transitional — cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181, 1999PubMedGoogle Scholar
  5. [5]
    Becker N, Wahrendorf J: Krebsatlas der Bundesrepublik Deutschland. 1981–1990.3.Auflage. Springer, Berlin (1997)Google Scholar
  6. [6]
    Bellmunt J, Guillem V, Paz-Ares L et al.: Phase I/II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 18:3247–3255, 2000PubMedGoogle Scholar
  7. [7]
    Böhle A, Block Th, Jakse G, Otto Th, Hofstädter F: Harnblasenkarzinom. In: Weißbach L, Miller K (Hrsg.): Qualitätssicherung in der Onkologie. Diagnostische und therapeutische Standards in der Urologischen Onkologie. W.Zuckschwerdt Verlag; S.30–64, 1998Google Scholar
  8. [8]
    Bono AV, Benvenuti C, Reali L, Pozzi E, Gibba A, Cosciani-Cunico S, Comuzzi U, Anselmo G: Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res 303:533–540, 1989PubMedGoogle Scholar
  9. [9]
    Boutan Laroze A, Mahjoubi M, Droz JP: M-VAC for advanced carcinoma of the bladder. The French Federation of Cancers Centers experience. Eur J Cancer 27:1690–1694, 1991CrossRefGoogle Scholar
  10. [10]
    Broome CM, Hussain M, Gutheil J: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Proc Amer Soc Clin Oncol 19:351a (abstract.1381), 2000Google Scholar
  11. [11]
    Cohen MH, Rothmann M: Gemcitabine and cisplatin for advanced, metastatic bladder cancer. J Clin Oncol 19:1229–1231, 2001PubMedGoogle Scholar
  12. [12]
    de Mulder PH, Debruyne FM, Keizer HJ, Ten Bokkel Huinick W, de Pauw M, Sylvester R: Randomized phase II study of methotrexate (M), cisplatin (C) and methotrexate, cisplatin and vinblastine (V) in patients with advanced transitional carcinoma of the bladder. Eur Urol 18 [Suppl.1] :5,1990Google Scholar
  13. [13]
    de Wit R, Tesselaar M, Kok TC: Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer. Eur J Cancer 27:1383–1385, 1991PubMedCrossRefGoogle Scholar
  14. [14]
    de Wit R, Kaye SB, Roberts JT: Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 67:388–390, 1993PubMedCrossRefGoogle Scholar
  15. [15]
    de Wit R, Kruit WH, Stoter G: Docetaxel (Taxotere): An active agent in metastatic urothelial cancer-results of a phase II study in nonchemotherapy — pretreated patients. Br J Cancer 78:1342–1345, 1998PubMedCrossRefGoogle Scholar
  16. [16]
    Freiha F, Reese J, Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155:495–499, 1996PubMedCrossRefGoogle Scholar
  17. [17]
    Gebbia V, Testa A, Borsellino N, Mauceri G, Varvara F, Tirritio Ml, Sambataro D, Fallica G: Single agent 2′, 2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma:a phase II study. Clin Ter 150:11–15, 1999PubMedGoogle Scholar
  18. [18]
    Hautmann RE, Miller K, Steiner U: The ileal neobladder: 6 years of experience with more than 200 patients. J Urol 150:40–45, 1993PubMedGoogle Scholar
  19. [19]
    Henly DR, Farrow GM and Zincke H: Urachal cancer: role of conservative surgery. Urology 42:635–639, 1993PubMedCrossRefGoogle Scholar
  20. [20]
    Herr HW: Urachal carcinoma: the case for extended partial cystectomy. J Urol 151:365–366, 1994PubMedGoogle Scholar
  21. [21]
    Hillcoat BL, Raghavan D, Matthews J: A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of urothelial tract. J Clin Oncol 7:706–712, 1989PubMedGoogle Scholar
  22. [22]
    Igawa M, Ohkucki T, Ueki T: Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144:662–665, 1990PubMedGoogle Scholar
  23. [23]
    Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921–1927, 2000PubMedGoogle Scholar
  24. [24]
    Khandekar JD, Elson PJ, de Wys WD, Slayton RE, Harris DT: Comparative activity and toxicity of cis-diaminedichloroplatinum in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3:539–549, 1985PubMedGoogle Scholar
  25. [25]
    Khorsand M, Lange J, Feun L: Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Proc Amer Soc Clin Oncol 15:297 (abstr.821), 1996Google Scholar
  26. [26]
    Kunze E: Formale Pathogenese des Harnblasenkarzinoms. In: Bichler K.-H., Wilbert D, Wechsel HW, Strohmaier WL: Diagnostik und Therapie des Harnblasenkarzinoms. Einhorn Presseverlag 1998Google Scholar
  27. [27]
    Llado A, Bellmunt J, Kaiser G, Baselga J: A dose finding study of carboplatin with fixed doses of gemcitabine in “unfit” patients with advanced bladder cancer. Proc Amer Soc Clin Oncol 19:344a, 2000Google Scholar
  28. [28]
    Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, StuartHarris R, Sarosdy MF, Lowe BA: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073, 1992PubMedGoogle Scholar
  29. [29]
    Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI: Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6:1590–1596, 1988PubMedGoogle Scholar
  30. [30]
    Logothetis CJ, Dexeus FH, Finn L: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055, 1990PubMedGoogle Scholar
  31. [31]
    Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala AG, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A: Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155:1241–1245, 1996PubMedCrossRefGoogle Scholar
  32. [32]
    Lorusso V, Manzione L, De Vita F,Antimi M, Selvaggi FP, De Lena: Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164:53–56, 2000PubMedCrossRefGoogle Scholar
  33. [33]
    Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG: The role of cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS, and P2). J Urol 144: 641–645,1990PubMedGoogle Scholar
  34. [34]
    Malmstrom PU, Rintala E, Wahlquist R, Hellstrom P, Nilsson S, Hellsten S, Hannisdal E: Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol 155:1903–1906, 1996PubMedCrossRefGoogle Scholar
  35. [35]
    Malmstrom PU, Rintala E, Wahlquist R, Hellstrom P, Nilsson S, Hellsten, and members of the Nordic Urothelial Cancer Group: Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic cystectomy trial 2. Eur Urol 35 (Suppl 12):60 (abstract 238), 1999Google Scholar
  36. [36]
    Mathur VK, Krahn HP, Ramsey E: Total cystectomy for bladder cancer. J Urol 125:784–788, 1981PubMedGoogle Scholar
  37. [37]
    McCaffrey JA, Hilton S, Mazumdar M: Phase II trial of docetaxel in patients with advanced or metastatic transitional — cell carcinoma. J Clin Oncol 15:1853–1857, 1997PubMedGoogle Scholar
  38. [38]
    Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441–3445, 1997PubMedGoogle Scholar
  39. [39]
    Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:2876–2881, 1999PubMedGoogle Scholar
  40. [40]
    Natale RB, Grossmann HB, Blumenstein B, Vogelzang N, Trump DL, Speights VO, de Vere White R, Crawford ED (2001): SWOG 8710 (INT-0080): Randomized Phase III Trial of Neoadjuvant MVAC + Cystectomy versus Cystectomy alone in patients with locally advanced Bladder Cancer. Plenary Presentation. Proc Amer Soc Clin Oncol 20:2a.Google Scholar
  41. [41]
    Nogue M, Carles J, Arrivi A, Garrido P: Palliative chemotherapy with gemcitabine and carboplatin in advanced transitional cell carcinoma of the urothelium — preliminary results. Proc Amer Soc Clin Oncol 19:345aGoogle Scholar
  42. [42]
    Papamichael D, Gallagher CJ, Oliver RT: Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 75:606–607, 1997PubMedCrossRefGoogle Scholar
  43. [43]
    Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33–64, 1999PubMedCrossRefGoogle Scholar
  44. [44]
    Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5:182–184, 1994PubMedGoogle Scholar
  45. [45]
    Raghavan D, Shipley WU, Garnick MD: Biology and management of bladder cancer. New Engl J Med 322:1129–1138 (1990)PubMedCrossRefGoogle Scholar
  46. [46]
    Roehrborn CG, Sagalowsky AI, Peters PC: Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146:36–39Google Scholar
  47. [47]
    Roth BJ, Dreicer R, Einhorn LH: Significant activity of paclitaxel in advanced transitional -cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264–2270, 1994PubMedGoogle Scholar
  48. [48]
    Santoro A, Santoro M, Maiorino L, Forestieri V, Forestieri P: Phase II trial of gemcitabine plus carboplatin for urothelial transitional cell carcinoma in advanced or metastatic stage. Ann Oncol 9:169, 1998Google Scholar
  49. [49]
    Skinner DG: Current perspectives in the management of high-grade invasive bladder cancer. Cancer 45(Suppl.7):1866–1874, 1980PubMedGoogle Scholar
  50. [50]
    Skinner DG, Lieskovsky G: Contemporary cystectomy with pelvic lymph node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 131:1069–1075, 1984PubMedGoogle Scholar
  51. [51]
    Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459–464, 1991PubMedGoogle Scholar
  52. [52]
    Solsona E, Iborra I, Ricos JV, Monros JL, Dumont R: Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: prospective study. J Urol 147:1513–1515, 1992PubMedGoogle Scholar
  53. [53]
    Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394–3398, 1997PubMedGoogle Scholar
  54. [54]
    Sternberg CN, Yagoda A, Scher HI: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403–407, 1985PubMedGoogle Scholar
  55. [55]
    Sternberg CN, Yagoda A, Scher HI: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64:2448–2458, 1989PubMedCrossRefGoogle Scholar
  56. [56]
    Sternberg CN, Scher HL: Management of invasive bladder neoplasm. In: Smith PH: Combination therapy in urological malignancy. London, Springer Verlag :95–118,1989CrossRefGoogle Scholar
  57. [57]
    Sternberg CN: The treatment of advanced bladder cancer. Ann Oncol 6:113–126,1995PubMedGoogle Scholar
  58. [58]
    Sternberg CN, de Mulder PH, Schornagel J, Theodore C, Fossa SD, Tirelli U, van Groeningen CJ, Colette L: Randomized phase III trial in advanced urothelial tract tumours of high dose intensity M-VAC chemotherapy and G-CSF versus classic MVAC. Proc Am Soc Clin Oncol 19: 1292 a, 2000Google Scholar
  59. [59]
    Sternberg CN, Calabro F: Neo-adjuvant chemotherapy in invasive bladder cancer. World J Urol 19:94–98, 2001PubMedCrossRefGoogle Scholar
  60. [60]
    Stoeckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R: Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153:47–52, 1995CrossRefGoogle Scholar
  61. [61]
    Stoeckle M, Meyenburg W, Wellek S, Voges GE, Fischer U, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R: Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48:868–875, 1996CrossRefGoogle Scholar
  62. [62]
    Stoter G: Chemotherapy for metastatic bladder carcinoma. World J Urol 3:110–119, 1985CrossRefGoogle Scholar
  63. [63]
    Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, Markwalder R, Senn E, Sonntag RW: Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152:81–84, 1994PubMedGoogle Scholar
  64. [64]
    Tannock I, Gospodarowicz M, Connoly J: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289–292, 1989PubMedGoogle Scholar
  65. [65]
    Thrasher JB and Crawford ED: Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149:957–972, 1993PubMedGoogle Scholar
  66. [66]
    Vaishampayan UN, Smith DC, Dickow B, Hussain M: Carboplatin, paclitaxel, and gemcitabine in advanced urothelial carcinoma: updated results. Proc Amer Soc Clin Oncol 19:341a, 2000Google Scholar
  67. [67]
    von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10: 1461–1465,1999PubMedCrossRefGoogle Scholar
  68. [68]
    von der Maase H, Hansen SW, Roberts PF, Oliver T, Moore M: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17: 3068–3077,2000Google Scholar
  69. [69]
    Yagoda A: Chemotherapy of urothelial tract tumors. Cancer 60:574–585, 1987PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • S. Machtens
  • P. Schöffski
  • M. Kuczyk

There are no affiliations available

Personalised recommendations